Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Activation of LANCL2 by BT-11 Ameliorates IBD by Supporting Regulatory T Cell Stability Through Immunometabolic Mechanisms.

Inflammatory bowel diseases - 16 Aug 2018

Leber Andrew, Hontecillas Raquel, Zoccoli-Rodriguez Victoria, Bassaganya-Riera Josep

Abstract excerpt

BACKGROUND: Inflammatory bowel disease (IBD) afflicts 5 million people and is increasing in prevalence. There is an unmet clinical need for safer and effective treatments for IBD. The BT-11 is a small molecule oral therapeutic that ameliorates IBD by targeting lanthionine synthetase C-like 2 (LANCL2) and has a benign safety profile in rats. METHODS: Mdr1a-/-, dextran sodium sulphate , and adoptive transfer mouse...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adoptive Transfer
Share to Benzimidazoles

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Colitis

Share to Dextran Sulfate

Share to Phosphate-Binding Proteins

Share to T-Lymphocyte Subsets

Share to T-Lymphocytes, Regulatory

Source

Open in PubMed Open full text

Identifiers

PMID: 29718324
DOI: 10.1093/ibd/izy167
PMCID: PMC6241665

Genes

LANCL2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Activation of LANCL2 by BT-11 Ameliorates IBD by Supporting Regulatory T Cell Stability Through Immunometabolic Mechanisms.PMID 29718324Read ↗

TL1A overexpression in Crohn’s Disease and mice alters Paneth cells and microbiota promoting ileal inflammationSemantic proximity Read ↗

CTLA-4 inhibitors drive colitis through metabolic reprogramming-mediated Treg/Th17 imbalanceSemantic proximity Read ↗

BT-11 repurposing potential for Alzheimer’s disease and insights into its mode of actionsSemantic proximity Read ↗

24-Nor-ursodeoxycholic acid counteracts T <sub>H</sub> 17/Treg imbalance and ameliorates intestinal inflammation by restricting glutaminolysis in differentiating T <sub>H</sub> 17 cellsSemantic proximity Read ↗

Multi-Targeted Anti-Cancer Mechanisms of Li-Ginseng Powder in Colitis-Associated Colorectal Cancer: Integrating Inflammation, Apoptosis and ImmunitySemantic proximity Read ↗

LRRK2 deficiency mitigates colitis progression by favoring resolution of inflammation and restoring homeostasis of gut microbiotaSemantic proximity Read ↗

Computational modeling-based discovery of novel classes of anti-inflammatory drugs that target lanthionine synthetase C-like protein 2.Semantic proximity Read ↗

Interleukin-21 Drives a Hypermetabolic State and CD4 <sup>+</sup> T Cell-associated Pathogenicity in Chronic Intestinal InflammationSemantic proximity Read ↗

Secondary bile acid lithocholic acid ameliorates colitis-like inflammation in a human intestine-on-chip systemSemantic proximity Read ↗

OLFM4 modulates intestinal inflammation by promoting IL-22+ILC3 in the gutSemantic proximity Read ↗

Fasting-mimicking diet-enriched Bifidobacterium pseudolongum suppresses colorectal cancer by inducing memory CD8 + T cellsSemantic proximity Read ↗

Harnessing the Biology of Canine Intestinal Organoids to Heighten Understanding of Inflammatory Bowel Disease Pathogenesis and Accelerate Drug Discovery: A One Health ApproachSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.